Advances in PGD2/PTGDR2 signaling pathway in tumors: A review

Authors

  • Hengjin Tian Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China; Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China
  • Kunpeng Ge Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China
  • Lulu Wang Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
  • Peiyao Gao Key Laboratory of Cancer Research and Clinical Laboratory Diagnosis, Bengbu Medical University, Bengbu, China
  • Amin Chen Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
  • Feifan Wang Department of Blood Transfusion, The First Affiliated Hospital of Naval Medical University, Shanghai, China
  • Fangzheng Guo Anhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical University, Bengbu, China
  • FengChao Wang Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China
  • Qiang Zhang Department of Clinical Laboratory, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China

DOI:

https://doi.org/10.17305/bb.2024.10485

Keywords:

Prostaglandins (PGs), prostaglandin D2 (PGD2), prostaglandin D2 receptor (PTGDR2), inflammation, cancer, signaling pathway

Abstract

Studies have shown that the prostaglandin (PG) family acts as an allergic inflammatory mediator in malignant diseases. Furthermore, prostaglandin E2 (PGE2) and its related receptors, as well as the prostaglandin D2 (PGD2)/PGD2 receptor (PTGDR2), play irreplaceable roles in tumorigenesis and anti-tumor therapy. Several experiments have demonstrated that PGD2 signaling through PTGDR2 not only directly inhibits cancer cell survival, proliferation, and migration but also reduces resistance toward conventional chemotherapeutic agents. Recent studies from our and other laboratories have shown that PGD2, its ligands, and related metabolites can significantly alter the tumor microenvironment (TME) by promoting the secretion of chemokines and cytokines, thereby inhibiting tumor progression. Additionally, reduced PGD2 expression has been associated with poor prognosis in patients with gastric, breast, lung, and pancreatic cancers, validating the preclinical findings and their clinical relevance. This review focuses on the current understanding of PGD2/PTGDR2 expression patterns and biological activity in cancer, proposing questions to guide the assessment of PGD2 and its receptors as potential targets for effective cancer therapies.

Citations

Downloads

Download data is not yet available.
Advances in PGD2/PTGDR2 signaling pathway in tumors

Downloads

Published

06-09-2024

Issue

Section

Review

Categories

How to Cite

1.
Advances in PGD2/PTGDR2 signaling pathway in tumors: A review. Biomol Biomed [Internet]. 2024 Sep. 6 [cited 2024 Oct. 5];24(5):1055–1067. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/10485